Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

CIT Group Inc. (CIT), MBIA Inc. (MBI): Fairholme & Bruce Berkowitz’s Bearish Moves; Should You Follow?

Page 1 of 2

Each quarter, hedge funds, such as Bruce Berkowitz’s Fairholme, file 13Fs with the SEC. The 13F forms disclose many of the positions held in the fund’s equity portfolio during the quarter. Fairholme is a very large managed fund, with over $19 billion assets under management, and has averaged an annual return of 12.9% over the past decade. We will now take a quick look at five stock positions that were either closed completely or reduced in the first quarter.

FAIRHOLME (FAIRX) Bruce Berkowitz

Why pay attention?

Retail investors can benefit from watching hedge fund sentiment. The top holdings of the best money managers can beat the market significantly. Discover the details of this strategy.


During the quarter, Berkowitz sold out of his entire stake, of 3,223,229 shares, in leasing company CIT Group Inc. (NYSE:CIT), worth about $124.5 million as of December 31, 2012. The company reported disappointing margins as well as floundering asset growth during the first quarter of 2013, and there do seem to be companies offering better value in the leasing company sector, with ORIX Corporation (ADR) (NYSE:IX), for example, trading at 0.97 times book, while CIT Group Inc. (NYSE:CIT) trades just above parity.

Up over 15% year-to-date, Wall Street thinks CIT Group Inc. (NYSE:CIT) doesn’t have much more room to run, with average price targets predicting just another 3% in upside from current levels. It’s possible that Berkowitz noticed the peaking valuation—in addition to the shrinking profitability measures—as key reasons to why he sold off his stake in the commercial financing company.

Fairholme also reportedly closed its 1,432,000-share position in investment banking company Jefferies Group, Inc. (NYSE:JEF), although this is likely due to the merger in December 2012 with Leucadia National Corp. (NYSE:LUK), which saw Jeffries become an LLC early in 2013. As of March 31, the fund still held 18,770,478 shares worth nearly $515 million in Leucadia.


The fund also decreased its stake in financial services company MBIA Inc. (NYSE:MBI) by approximately 26%, to hold 31,425,820 shares worth over $322 million as of the end of Q1. MBIA Inc. (NYSE:MBI) recently won a successful settlement against Bank of America Corp (NYSE:BAC), causing a 40% rise in its share price; Berkowitz’s sale during the quarter may have been an attempt to hedge against the uncertainty created by the case, although if so, this proved to be unnecessary.

Despite its massive appreciation of late, MBIA Inc. (NYSE:MBI) still sports the fourth-lowest PEG ratio in the entire financial sector (0.20), a book valuation below parity (0.83), and bargain bin multiples nearly everywhere else you look. Yes, earnings have been spotty, but much of the regulatory fears have been lifted, and Wall Street does expect MBIA Inc. (NYSE:MBI) to generate earnings growth of 10% a year over the next half-decade.

Fundamentally speaking, this play reminds us of an early 2012-era American International Group Inc (NYSE:AIG); shares have risen, but are still extremely cheap. Quite frankly, there’s nothing preventing more value hunters from buying in at these levels too.

Interestingly, another substantial decrease during the quarter was in Wells Fargo & Co (NYSE:WFC), with the fund reducing its existing stake by about a quarter to 151,400 shares worth about $5.6 million, as at March 31, 2013. This is an interesting move, given that Warren Buffett increased his holdings in the company during the quarter; the company has also reported positive quarterly earnings, and should continue to benefit from an ongoing housing boom, particularly in its home lending division.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!